The startup is developing a pharmaceutical platform that focuses on non-opioid pain therapeutics, featuring four drug candidates targeting both acute and chronic pain. This platform provides patients with effective alternatives to opioids, addressing the need for viable analgesics in both hospital and retail settings.
Funding
$55.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current pain management treatments, particularly opioids, carry significant risks of abuse, misuse, diversion, and life-threatening side effects such as respiratory depression. There is a need for effective and safe non-opioid alternatives for both acute and chronic pain management in hospital and retail settings. Existing non-opioid analgesics, such as NSAIDs and gabapentinoids, have limitations including gastrointestinal, cardiovascular, and neurological side effects, as well as unpredictable efficacy.
Solution
Neumentum is a pharmaceutical company focused on developing and commercializing non-opioid analgesics to address the unmet need for safer and more effective pain management options. Their pipeline includes four novel non-opioid products in development targeting both acute and chronic pain. These products are designed to provide analgesia without the risks associated with opioids, such as addiction and respiratory depression, and to overcome the limitations of existing non-opioid treatments. Neumentum's lead product candidates include NTM-001, a novel formulation of ketorolac for continuous infusion, and NTM-006, a new chemical entity with a novel mechanism of action for oral administration.
Target Audience
The primary target audience includes patients experiencing acute or chronic pain, healthcare providers seeking non-opioid alternatives for pain management, and hospitals aiming to reduce opioid use and improve patient outcomes.
Features
- NTM-001: A novel, alcohol-free formulation of ketorolac in a pre-mixed bag for continuous intravenous infusion, designed to deliver 24 hours of opioid-level analgesia for moderately-severe pain.
- NTM-001: Aims to reduce analgesic gaps associated with bolus ketorolac administration and potentially shorten hospital stays.
- NTM-006: A non-opioid, non-NSAID, non-gabapentinoid new chemical entity (NCE) with a novel mechanism of action (MOA) for once- or twice-daily oral administration.
- NTM-006: Preclinical evidence suggests NTM-006 exerts its analgesic activity via Adenosine A3 Receptor Modulation (ARM).
- Early-stage pipeline includes a short infusion of ketorolac PMB for acute pain and two non-opioid NCE analgesic compounds with the potential to provide powerful efficacy without the liver toxicity associated with acetaminophen (APAP).